ESMO 2014: AstraZeneca's AZD9291 and Iressa

1 October 2014

Data presented during the European Society for Medical Oncology (ESMO) congress included study results from Anglo-Swedish drug major AstraZeneca (LSE: AZN) which presented updated data from the ongoing AURA Phase I/II study investigating AZD9291 in patients with advanced non-small cell lung cancer.

The company said the investigational drug shows encouraging, although still immature, median progression free survival of 9.6 months in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced NSCLC who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI). The progression free survival (PFS) results are based on a 30% data maturity from 138 patients.

As of August 1, 253 pre-treated patients have been dosed on this study and the 80mg once daily dose has been selected for late stage development. The PFS results were coupled with a prolonged duration of response. In patients with EGFRm T790M+ advanced NSCLC treated at the 80mg dose, the preliminary median duration of response was 8.2 months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK